Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

My dart is at least 50% PASI 75 in early March.

New Information: Greatest Efficacy Seen in Patients with Moderate Psoriasis

Among patients participating in the study with the severest form of psoriasis, those having a baseline IGA score of 3 (“moderate”), the primary endpoint was met in 46.2% of patients who received Prurisol 200mg. This data was derived from analyses of all patients randomized across all 9 participating study sites.

http://www.ipharminc.com/press-release/2016/11/12/cellceutix-provides-additional-insight-into-successful-phase-2-trial-for-treating-psoriasis